Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Murry W. Wynes"'
Autor:
Madhusmita Behera, PhD, Renjian Jiang, MS, Zhonglu Huang, MS, Becky Bunn, MS, Murry W. Wynes, PhD, Jeffrey Switchenko, PhD, Giorgio V. Scagliotti, MD, Chandra P. Belani, MD, Suresh S. Ramalingam, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 6, Pp 100592- (2024)
Introduction: EGFR exon 20 insertion (ex20ins) mutations account for approximately 10% of EGFR mutations in lung adenocarcinoma. Patients with ex20ins mutation do not respond to standard EGFR tyrosine kinase inhibitor therapy. In this work, we analyz
Externí odkaz:
https://doaj.org/article/f92ad290cb7e478fb92426609abe2a43
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 1 (2009)
Epidermal growth factor receptor (EGFR) related therapies - mainly tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib, but also monoclonal antibodies targeting EGFR, for example, cetuximab - have been investigated in numerous settings
Externí odkaz:
https://doaj.org/article/12f14f02125648799b117f7318a2c7a4
Autor:
Fred R. Hirsch, Norihiko Ikeda, Tatuso Ohira, Koichi Yoshida, Toshitaka Nagao, Jun Matsubayashi, Fabien Gaire, Jim Ranger-Moore, Mark Gustavson, Jason M. Zhao, Bernadette Reyna Asuncion, Cindy Tran, Yasufumi Kato, Murry W. Wynes, Celine Mascaux
PDF file - 162KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9191cb4ff9ccf83a96a0f581614ab7c
https://doi.org/10.1158/1078-0432.22446437.v1
https://doi.org/10.1158/1078-0432.22446437.v1
Autor:
Fred R. Hirsch, Norihiko Ikeda, Tatuso Ohira, Koichi Yoshida, Toshitaka Nagao, Jun Matsubayashi, Fabien Gaire, Jim Ranger-Moore, Mark Gustavson, Jason M. Zhao, Bernadette Reyna Asuncion, Cindy Tran, Yasufumi Kato, Murry W. Wynes, Celine Mascaux
PDF file - 122KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::797a4d04163fe677be6306e6b6063440
https://doi.org/10.1158/1078-0432.22446434
https://doi.org/10.1158/1078-0432.22446434
Autor:
Lynn E. Heasley, Fred R. Hirsch, Aik-Choon Tan, D. Ross Camidge, Paul A. Bunn, Joseph M. Gozgit, Aleksandra Sejda, Szymon Wojtylak, Jacek Jassem, Rafal Dziadziuszko, Barbara A. Helfrich, Sven Perner, Diana Böhm, Michael G. Edwards, Kathryn E. Ware, Lindsay A. Marek, Michael Martini, Dexiang Gao, Trista K. Hinz, Murry W. Wynes
XLSX file - 66KB, Table S1. Compiled and tabulated ponatinib IC50 values, FGF and FGFR expression, FGFR1 gene copy number and characteristics of the 58 lung cancer cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f86a1094ac57d8c9fdf3604136391e
https://doi.org/10.1158/1078-0432.22457078
https://doi.org/10.1158/1078-0432.22457078
Autor:
Fred R. Hirsch, Norihiko Ikeda, Tatuso Ohira, Koichi Yoshida, Toshitaka Nagao, Jun Matsubayashi, Fabien Gaire, Jim Ranger-Moore, Mark Gustavson, Jason M. Zhao, Bernadette Reyna Asuncion, Cindy Tran, Yasufumi Kato, Murry W. Wynes, Celine Mascaux
PDF file - 73KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a750bf580a6b86b0915711642d07c79
https://doi.org/10.1158/1078-0432.22446431.v1
https://doi.org/10.1158/1078-0432.22446431.v1
Autor:
Lynn E. Heasley, Fred R. Hirsch, Aik-Choon Tan, D. Ross Camidge, Paul A. Bunn, Joseph M. Gozgit, Aleksandra Sejda, Szymon Wojtylak, Jacek Jassem, Rafal Dziadziuszko, Barbara A. Helfrich, Sven Perner, Diana Böhm, Michael G. Edwards, Kathryn E. Ware, Lindsay A. Marek, Michael Martini, Dexiang Gao, Trista K. Hinz, Murry W. Wynes
PDF file - 786KB, Figure S1. FGFR1 immunoblots of extracts from lung cancer cell lines representative of the 58 cell lines employed in the studies. Figure S2. Images and quantification of clonogenic growth assays in selected lung cancer cell lines fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bac78c4c44ca4b29efcee64013e1db
https://doi.org/10.1158/1078-0432.22457081.v1
https://doi.org/10.1158/1078-0432.22457081.v1
The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce8b8d4a8da07eb2f6509cc301a0b90d
https://doi.org/10.1158/1078-0432.c.6519393
https://doi.org/10.1158/1078-0432.c.6519393
Autor:
Lynn E. Heasley, Fred R. Hirsch, Aik-Choon Tan, D. Ross Camidge, Paul A. Bunn, Joseph M. Gozgit, Aleksandra Sejda, Szymon Wojtylak, Jacek Jassem, Rafal Dziadziuszko, Barbara A. Helfrich, Sven Perner, Diana Böhm, Michael G. Edwards, Kathryn E. Ware, Lindsay A. Marek, Michael Martini, Dexiang Gao, Trista K. Hinz, Murry W. Wynes
XLSX file - 106KB, Table S5. Tabulated FGFR1, FGF2 and FGF9 mRNA expression values, FGFR1 CNV values and mutation status of TCGA lung adenocarcinomas and squamous cell carcinomas.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::800d499327ad7e09fcfd88c8fee6c51d
https://doi.org/10.1158/1078-0432.22457075
https://doi.org/10.1158/1078-0432.22457075
Related Article from The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a0fde444585963547914307d5ce8743
https://doi.org/10.1158/1078-0432.22442724
https://doi.org/10.1158/1078-0432.22442724